文献速递糖尿病

达格列净对2型糖尿病患者住院的影响:DECLARE-TIMI 58试验的事后分析

Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2023-03-03

DECLARE-TIMI 58试验事后分析纳入17160例2型糖尿病患者,随机接受达格列净10 mg每日一次或安慰剂。中位随访4.2年,达格列净降低全因非选择性首次住院风险(HR 0.89 [95% CI 0.85-0.94])和总住院风险(RR 0.92 [95% CI 0.86-0.97]),且不论有无动脉粥样硬化性心血管疾病。

要点

  • 达格列净降低全因非选择性首次住院风险:HR 0.89(95% CI 0.85-0.94)。
  • 达格列净降低全因非选择性总住院风险:RR 0.92(95% CI 0.86-0.97)。
  • 有无动脉粥样硬化性心血管疾病亚组间疗效一致(p交互=0.31)。

核心结论

  • 达格列净降低2型糖尿病患者全因非选择性首次和总住院风险,不论有无动脉粥样硬化性心血管疾病,包括非直接归因于心脏、肾脏或代谢原因的住院。

研究设计与样本

  • DECLARE-TIMI 58试验为双盲、多中心、随机、安慰剂对照研究,患者随机(1:1)接受口服达格列净10 mg或安慰剂每日一次。
  • 2013年4月25日至2018年9月18日共纳入17160例(6422例[37.4%]女性,10738例[62.6%]男性;平均年龄63.9岁[SD 6.8])。
  • 事后分析采用Cox比例风险回归模型评估首次非选择性全因和特定原因住院风险,采用Lin-Wei-Ying-Yang模型评估总(首次加后续)非选择性住院风险。
  • 特定原因住院按研究者报告的系统器官分类(System Organ Class)术语分类。

主要发现

  • 中位随访4.2年(IQR 3.9-4.4),达格列净组全因非选择性首次住院2779/8582例(32.4%),安慰剂组3036/8578例(35.4%),HR 0.89(95% CI 0.85-0.94)。
  • 达格列净组全因非选择性总住院风险比0.92(95% CI 0.86-0.97)。
  • 有动脉粥样硬化性心血管疾病亚组HR 0.92(95% CI 0.85-0.99),无该疾病亚组HR 0.87(95% CI 0.81-0.94),p交互=0.31。
  • 达格列净组心脏疾病住院HR 0.91(95% CI 0.84-1.00),代谢和营养障碍住院HR 0.73(95% CI 0.60-0.89),肾脏和泌尿系统疾病住院HR 0.61(95% CI 0.49-0.77),排除上述三类后的其他原因住院HR 0.90(95% CI 0.85-0.96)。
  • 达格列净组肌肉骨骼和结缔组织疾病住院HR 0.81(95% CI 0.67-0.99),感染和寄生虫病住院HR 0.86(95% CI 0.78-0.96)。

关键数值与推荐

  • 达格列净10 mg口服每日一次。
  • 10186例(59.4%)有多种危险因素但无 established 动脉粥样硬化性心血管疾病,6835例(39.8%)无动脉粥样硬化性心血管疾病证据且KDIGO风险低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In people with type 2 diabetes at high risk of cardiovascular or kidney disease, sodium-glucose co-transporter 2 (SGLT2) inhibitors consistently reduce the risk of hospitalisations for heart failure. Less is known about their effects on hospitalisation from any cause, especially in people with type 2 diabetes without atherosclerotic cardiovascular disease, which includes most of the global population of people with type 2 diabetes. We aimed to assess the effect of the SGLT2 inhibitor, dapagliflozin, on the risks of hospitalisations for any cause and for specific causes in people with type 2 diabetes with and without atherosclerotic cardiovascular disease. METHODS: The DECLARE-TIMI 58 trial was a double-blind, multicentre, randomised, placebo-controlled study. People with type 2 diabetes and either risk factors for or established atherosclerotic cardiovascular disease were randomly assigned (1:1) to receive oral dapagliflozin 10 mg or placebo once daily. In these post-hoc analyses, the effects of dapagliflozin on risks of first non-elective any-cause and cause-specific hospitalisation were assessed with Cox proportional hazards regression models overall and in the subset of participants without prevalent atherosclerotic cardiovascular disease. The risk of total (first plus subsequent) non-elective hospitalisations was assessed with Lin-Wei-Ying-Yang model. Investigator-reported System Organ Class terms were used to classify cause-specific hospitalisations. The trial is registered with ClinicalTrials.gov, NCT01730534. FINDINGS: Between April 25, 2013, and Sept 18, 2018, 17 160 people (6422 [37·4%] women, 10 738 [62·6%] men; mean age 63·9 years [SD 6·8]) were enrolled in the original trial, of whom 10186 (59·4%) had multiple risk factors for but did not have established atherosclerotic cardiovascular disease, and 6835 (39·8%) had both no evidence of atherosclerotic cardiovascular disease and low KDIGO risk. Over a median follow-up of 4·2 years (IQR 3·9-4·4), dapagliflozin was associated with a lower risk of first non-elective hospitalisation for any cause (2779 [32·4%] of 8582 people in the dapagliflozin group vs 3036 [35·4%] of 8578 people in the placebo group; hazard ratio [HR] 0·89 [95% CI 0·85-0·94]) and total (first plus subsequent) non-elective hospitalisations for any cause (risk ratio 0·92 [95% CI 0·86-0·97]). The association between dapagliflozin use and the risk of first non-elective hospitalisation for any cause was consistent in subgroups of participants with (HR 0·92 [95% CI 0·85-0·99] and without (0·87 [0·81-0·94]) atherosclerotic cardiovascular disease at baseline (p interaction=0·31). Compared with the placebo group, the dapagliflozin group had lower risk of first hospitalisations due to cardiac disorders (HR 0·91 [95% CI 0·84-1·00]), metabolism and nutrition disorders (0·73 [0·60-0·89]), renal and urinary disorders (0·61 [0·49-0·77]), and due to any other cause excluding these three causes (0·90 [0·85-0·96]). Treatment with dapagliflozin was also associated with a lower risk of hospitalisations due to musculoskeletal and connective tissue disorders (HR 0·81 [0·67-0·99]) and infections and infastations (HR 0·86 [0·78-0·96]). INTERPRETATION: Dapagliflozin reduced the risk of first and total non-elective hospitalisations for any cause in people with type 2 diabetes, regardless of the presence of atherosclerotic cardiovascular disease, including hospitalisations not directly attributed to cardiac, kidney, or metabolic causes. These findings might have implications on health-related quality of life for people with type 2 diabetes and on health-care costs attributable this condition. FUNDING: AstraZeneca.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Schechter M, Wiviott SD, Raz I, et al. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. Lancet Diabetes Endocrinol. 2023. PMID: 36878239. doi:10.1016/S2213-8587(23)00009-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。